Department of Health Services, Policy, and Practice, Brown University School of Public Health, 121 South Main Street, Box G-S121-6, Providence, RI, 02912, USA.
Center for Gerontology and Healthcare Research, Brown University School of Public Health, Providence, RI, USA.
Addict Sci Clin Pract. 2022 Oct 8;17(1):57. doi: 10.1186/s13722-022-00338-x.
Hospitalizations involving opioid use disorder (OUD) have been increasing among Medicare beneficiaries of all ages. With rising OUD-related acute care use comes the need to understand where post-acute care is provided and the capacities for OUD treatment in those settings. Our objective was to describe hospitalized Medicare beneficiaries with OUD, their post-acute care locations, and all-cause mortality and readmissions stratified by post-acute care location.
We conducted a retrospective cohort study of acute hospitalizations using 2016-2018 Medicare Provider Analysis and Review (MedPAR) files linked to Medicare enrollment data and the Residential History File (RHF) for 100% of Medicare fee-for-service beneficiaries. The RHF which provides a person-level chronological history of health service utilization and locations of care was used to identify hospital discharge locations. We used ICD-10 codes for opioid dependence or "abuse" to identify OUD diagnoses from the MedPAR file. We conducted logistic regression to identify factors associated with discharge to an institutional setting versus home adjusting for demographics, comorbidities, and hospital stay characteristics.
Our analysis included 459,763 hospitalized patients with OUD. Of these, patients aged < 65 years and those dually enrolled in Medicaid comprised the majority (59.1%). OUD and opioid overdose were primary diagnoses in 14.3% and 6.2% of analyzed hospitalizations, respectively. We found that 70.3% of hospitalized patients with OUD were discharged home, 15.8% to a skilled nursing facility (SNF), 9.6% to a non-SNF institutional facility, 2.5% home with home health services, and 1.8% died in-hospital. Within 30 days of hospital discharge, rates of readmissions and mortality were 29.7% and 3.9%; respectively, with wide variation across post-acute locations. Factors associated with greater odds of discharge to institutional settings were older age, female sex, non-Hispanic White race and ethnicity, dual enrollment, longer hospital stay, more comorbidities, intensive care use, surgery, and primary diagnoses including opioid or other drug overdoses, fractures, and septicemia.
More than one-quarter (25.8%) of hospitalized Medicare beneficiaries with OUD received post-acute care in a setting other than home. High rates and wide variation in all-cause readmissions and mortality within 30 days post-discharge emphasize the need for improved post-acute care for people with OUD.
在所有年龄段的医疗保险受益人中,涉及阿片类药物使用障碍(OUD)的住院治疗一直在增加。随着 OUD 相关急性护理使用的增加,需要了解在哪里提供后续急性护理,以及在这些环境中治疗 OUD 的能力。我们的目的是描述患有 OUD 的住院医疗保险受益人、他们的后续急性护理地点以及按后续急性护理地点分层的全因死亡率和再入院率。
我们使用 2016-2018 年医疗保险提供者分析和审查(MedPAR)文件进行了一项回顾性队列研究,该文件与医疗保险登记数据和 100%医疗保险按服务付费受益人的居住史文件(RHF)相关联。RHF 提供了一个人的健康服务利用和护理地点的时间顺序历史,用于确定医院出院地点。我们使用 ICD-10 代码来确定阿片类药物依赖或“滥用”,以从 MedPAR 文件中确定 OUD 诊断。我们进行了逻辑回归分析,以确定与出院到机构环境而不是家庭相关的因素,调整了人口统计学、合并症和住院特征。
我们的分析包括 459763 名患有 OUD 的住院患者。其中,年龄<65 岁的患者和同时参加医疗补助计划的患者占大多数(59.1%)。OUD 和阿片类药物过量分别是分析住院治疗中 14.3%和 6.2%的主要诊断。我们发现,70.3%的患有 OUD 的住院患者出院回家,15.8%出院到熟练护理设施(SNF),9.6%出院到非 SNF 机构设施,2.5%在家接受家庭健康服务,1.8%住院期间死亡。在出院后 30 天内,再入院和死亡率分别为 29.7%和 3.9%;分别在不同的后续治疗地点存在较大差异。与更有可能出院到机构环境相关的因素包括年龄较大、女性、非西班牙裔白人种族和民族、双重登记、住院时间较长、更多合并症、重症监护使用、手术以及包括阿片类药物或其他药物过量、骨折和败血症在内的主要诊断。
超过四分之一(25.8%)患有 OUD 的住院医疗保险受益人在家庭以外的环境中接受了后续急性护理。出院后 30 天内全因再入院和死亡率的高发生率和广泛差异强调了需要改善患有 OUD 的人的后续急性护理。